Abstract: A class of Glycine B partial agonists is described for use in memory and learning enhancement or for treatment of a cognitive disorder. Preferred Glycine B partial agonists include the compound D-cycloserine and its prodrug compounds.

Abstract: Solid compositions of certain cholinergic compounds are stabilized in starch. Especially compositions of corn starch combined or mixed with the 0-substituted-1,2,5,6-tetrahydro-3-pyridine oxime ether, CI-979 HCl, a cognition activator, have been found stable in a heated environment of up to 60.degree. C. over 17 days such that no losses were detected by HPLC analysis. A solid peroral pharmaceutical formulation for the treatment of cognitive disorders is based on the bicomponent composition of active ingredient and stabilizer using appropriate amounts of other excipients or components known in the formulation art.

Abstract: The invention relates to a 3-quinuclidine derivative having the formula I ##STR1## wherein X is O or S, and R represents one to five substituents independently selected from hydrogen, hydroxy, lower alkyl, lower alkoxy, lower aralkyloxy, lower alkanoyloxy, halogen, NO.sub.2, CF.sub.3, CN, NR.sub.1 R.sub.2, and COR.sub.3, in which R.sub.1 and R.sub.2 are independently selected from hydrogen, lower alkyl, and lower alkanoyl, and R.sub.3 is selected from OH, lower alkyl, lower alkoxy, and NR.sub.4 R.sub.5, wherein R.sub.4 and R.sub.5 are independently hydrogen or lower alkyl; or pharmaceutically acceptable salts thereof.

Abstract: A method for treating ALS (Amyotrophic Lateral Sclerosis) is disclosed. The inventive method comprises the administration of controlled dosages of dextromethorphan in therapeutically effective amounts in a pharmaceutically acceptable vehicle Dextromethorphan (DMP) is a dimethylaminomethyl-substituted phenol, a sigma receptor antagonist known also as d-3-methoxy-N methylmorphinan, a d-isomer of the codeine analog, levorphanol. The inventive method has proven useful in controlling the progression of ALS in afflicted patients.

Abstract: The invention relates to the use of a compound selected from those of formula (I): ##STR1## in which R, R.sub.1, R.sub.2 and n are as defined in the description, for the treatment of cholinergic transmission disorders.

Abstract: The invention relates to compounds of formula (I): ##STR1## in which: A represents, with the carbon and nitrogen atoms to which it is linked, cyclic amide as defined in the description,B represents, with the nitrogen and carbon atoms to which it is linked, saturated polycyclic structure as defined in the description,R represents hydrogen, optionally substituted lower alkyl, optionally substituted (4-imidazolyl)methyl, (3-pyrazolyl)methyl or optionally substituted (2-pyridyl)methyl,their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid.Medicinal products.

Abstract: L-Deprenyl and pharmaceutically acceptable analog forms thereof are used at specific dosage levels and frequency of dosage to slow the normal age dependent deterioration of renal function, to provide increased exploratory behavior level of activity at any given age and in order to retard age deterioration of cognitive abilities, especially spatial learning ability. The treatment can be especially useful for mammals, for examples pets such as dogs and cats.

Abstract: Ginsenosides Rb.sub.1 and Rg.sub.1 enhance the availability of acetylcholine in the cortical and hippocampal regions of the brain and alleviaate the symptoms of Alzheimer-type senile dementia. The Rb.sub.1 or Rg.sub.1 may be administered together with a metabolic precursor for acetylcholine and/or with a cholinesterase inhibitor.Pure Rb.sub.1 is located from a mixture of ginsenosides by a process involving vacuum chromatography on silica gel. Preferably, the mixture of ginsenosides is enriched in Rb.sub.1 by partition between an aqueous system and water ethyl acetatebutanol.

Abstract: A method for treating or preventing neuronal injury in a mammal, comprising the step of administering in vivo a therapeutically effective amount of a long-chain fatty alcohol having from about 23 to about 29 carbon atoms or prodrug esters thereof. Also disclosed are pharmacological compositions containing from 0.01 mg/kg to about 20 mg/kg of the fatty alcohol. The method and compositions are useful in: treating traumatic injury, chemical injury and injury due to disease; promoting and accelerating recovery of behavioral function after such injury; preventing neuronal injury or death; improving training and memory functions; and protecting neurons against injury.

Abstract: Premenstrual syndrome (PMS) and other conditions may be diagnosed according to the invention by measuring the level of luteinizing hormone antibodies in the system of a woman subject. A low level of such antibodies as compared to levels measured for non-PMS women indicates that the patient suffers from PMS. A patient identified by this method is then treated as needed, such as by oral administration of progesterone, to alleviate the symptoms of the condition.

Abstract: The present invention relates to a transdermal therapeutical system for the administration of physostigmine to the skin via a cover layer which is impermeable to active substances, a pressure-sensitive adhesive reservoir layer, and optionally a removable protective layer, said reservoir layer consisting of 10-90% polymeric material selected from the groups consisting of block copolymers on the basis of styrene and 1,3-dienes, polyisobutylenes, polymers on the basis of acrylates and/or methacrylates and esters of hydrogenated colophonium, 0-30%-wt softeners on the basis of hydrocarbons and/or esters, and 0.1-20%-wt physostigmine.

Abstract: Administration of a Growth Hormone Releasing factor (GRF) at effective dosage levels improves the mental function of attention or short term memory in a subject in need of the treatment. The method of treating comprises the administration to the subject of an effective mental function improving amount of a Growth Hormone Releasing Factor.

Abstract: New morpholine compounds of the formula: ##STR1## in which: X, bonded to the aromatic nucleus, represents halogen or trifluoromethyl and R' represents hydrogen, (C.sub.1 -C.sub.5)alkyl optionally including a double bond, or aralkyl; in racemic and enantiomeric forms, and physiologically tolerable acid addition salts theroef.These compounds and their physiologically tolerable salts can be used therapeutically especially in the treatment of ischaemic syndromes and cerebral ageing.

Abstract: Novel prodrugs or depot derivatives of 1,2,3,4-tetrahydro-9-acridinamine are described, as well as methods for the preparation and pharmaceutical compositions of same, which are useful as analgesic agents for the treatment of pain, as sleep aids and as agents for treating the symptoms of senile dementia, Alzheimer's disease, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, or similar conditions of cerebral insufficiency characterized by decreased cerebral acetylcholine production or release.

Abstract: Ginsenosides Rb.sub.1 and Rg.sub.1 enhance the avaiability of acetylcholine in the cortical and hippocampal regions of the brain and alleviate the symptoms of Alzheimer-type senile dementia.Pure Rb.sub.1 is isolated from a mixture of ginsenosides by a process involving vacuum chromatography on silica gel. Preferably, the mixture of ginsenosides is enriched in Rb.sub.1 by partition between an aqueous system and water ethyl acetatebutanol.

Abstract: The administration of Somatostatin and growth hormone releasing factor at useful dosage levels alleviates the symptoms of various neuropsychiatric disorders.Growth hormone and neuropsychiatric responses to the administration of growth hormone releasing factor to mammals indicate its usefulness as an antemortem marker for senile dementia of the Alzheimer's type.

Abstract: A method of treating humans suffering from central nervous system diseases, such as Alzheimer's disease, Parkinsons's disease, senile dementia. The treatment consists of inducing into the patient's blood stream at least one from the group consisting of: sex hormones and anabolic hormones. Growth hormone is also be used in those patients in advanced stages of the disease, or in those patients where it has been determined that a low level of growth hormone is present. A method of diagnosing Alzheimer's disease, senile dementia, by the determination of the levels of the hormones somatotropin (human growth hormone) and somatomedin-C (IGF-I) after the administration of the Aroonsakul-Allen provocative test is also disclosed. Blood-sera samples are taken at certain time periods after the administration of L-Dopa, and the samples are tested for the levels of these hormones. These levels are then compared against the levels for normal subjects.

Abstract: A method of treating humans suffering from central nervous system diseases, such as Alzheimer's disease, Parkinson's disease, senile dementia. The treatment consists of inducing into the patient's blood stream at least one from the group consisting of: sex hormones and anabolic hormones. Growth hormone is also be used in those patients in advanced stages of the disease, or in those patients where it has been determined that a low level of growth hormone is present. A method of diagnosing Alzheimer's disease, senile dementia, by the determination of the levels of the hormones somatotropin (human growth hormone) and somatomedin-C (IGF-I) after the administration of the Aroonsakul-Allen provocative test is also disclosed. Blood-sera samples are taken at certain time periods after the administration of L-Dopa, and the samples are tested for the levels of these hormones. These levels are then compared against the levels for normal subjects.

Abstract: A method of treating humans suffering from central nervous system diseases, such as Alzheimer's disease, Parkinson's disease, senile dimentia. The treatment consists of inducing into the patient's blood stream at least one from the group consisting of: sex hormones and anabolic hormones. Growth hormone is also be used in those patients in advanced stages of the disease, or in those patients where it has been determined that a low level of growth hormone is present. A method of diagnosing Alzheimer's disease, senile dementia, by the determination of the levels of the hormones somatotropin (human growth hormone) and somatomedin-C (IGF-I) after the administration of the Aroonsakyl-Allen provocative test is also disclosed. Blood-sera samples are taken at certain time periods after the administration of L-Dopa, and the samples are tested for the levels of these hormones. These levels are then compared against the levels for normal subjects.

Abstract: A method of treating human suffering from central nervous system diseases, such as Alzheimer's disease, Parkinson's disease, senile dementia. The treatment consists of inducing into the patient's blood stream at least one from the group consisting of: sex hormones and anabolic hormones. Growth hormone is also being used in those patients in advanced stages of the disease, or in those patients where it has been determined that a low level of growth hormone is present. A method of diagnosing Alzheimer's disease, senile dementia, by the determination of the levels of the hormones somatotropin (human growth hormone) and somatomedin-C (IGF-I) after the administration of the Aroonsakul-Allen provocative test is also disclosed. Blood-sera samples are taken at certain time periods after the administration of L-Dopa, and the samples are tested for the levels of these hormones. These levels are then compared against the levels for normal subjects.

Abstract: Disclosed are e.g. certain novel 2-benzyl-3-(substituted)-phenoxypropylamines, their methods of synthesis and pharmaceutical compositions. Said compounds are useful as potent and centrally active serotonin uptake inhibitors for the treatment of psychotropic disorders, particularly depression.

Abstract: A method of treating a relatively aged animal to reverse age-related changes in the lipid composition of organ and tissue cells, such as heart muscle cells, and the ability of the animal to withstand respiratory stress. A suspension of small unilamellar vesicles composed predominantly of egg phosphatidyl choline is administered parenterally to the animal, preferably over a period of several days and at a dose level of between about 0.1 and 1 grams lipid per kg body weight per day. Changes in the heart muscle cells are reflected in decreased levels of serum creatine phosphokinase. Liposome administration is continued until the serum creatine phosphokinase level drops at least about 50%. Also disclosed are liposome treatment methods for increasing longevity and male fertility.

Abstract: Morpholine compounds of the formula: ##STR1## in which R.sub.1 is hydrogen, straight-chain or branched (C.sub.1 -C.sub.6)-alkyl which may contain a double bond, aralkyl which may be substituted, (C.sub.5 -C.sub.6)-cycloalkyl or (C.sub.2 -C.sub.6)-acyl; andR.sub.2 is hydrogen, straight-chain or branched (C.sub.1 -C.sub.6)-alkyl which may contain a double bond, aralkyl which may be substituted, or (C.sub.2 -C.sub.3)-acyl; enantiomers and physiologically tolerable acid salts thereof.These compounds may be used therapeutically especially in the treatment of ischaemic syndromes and of cerebral ageing.

Abstract: A derivative of benzoquinonylphenyl alkanoic acid amide having the formula: ##STR1## wherein X represents an oxygen atom, sulfur atom, or methylated nitrogen atom, Me represents methyl, and n is 2 or 3. This derivative is effective as a cerebral insufficiency improver.

Abstract: Terguride and its physiologically compatible salts can be used for the treatment of geriatric deficiencies, e.g., in doses of 0.1-5.0 mg/day.

Abstract: A method is provided for orally treating a patient suffering from senile dementia which comprises the periodic oral delivery of a pharmaceutically effective amount of 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to said patient, whereby the patient tends to reduce his food intake. Also provided is an oral sustained release dosage unit form suitable for treating a patient suffering from obesity which permits a prolonged interval between administration to said patient, said oral dosage unit formulation comprising a plurality of granules which together constitute a pharmaceutically effective amount of 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to provide a sustained action over said prolonged interval, said plurality of granules each comprising a polymeric matrix to permit a substantially even release of said 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to permit the necessary sustained release over the prolonged period of time.